BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Haloperidol readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Haloperidol\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05431595-8908@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Haloperidol: Phase 2/3 readout est. (NCT05431595)
DESCRIPTION:Haloperidol\, phase 2/3.\nStudy: Managing Agitated Delirium Wit
 h Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy\nEsti
 mated primary completion: 2 February 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/haloperidol#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05431595
URL:https://assetmemo.bio/drug/haloperidol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06218524-8908@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Haloperidol: Phase 2 readout est. (NCT06218524)
DESCRIPTION:Haloperidol\, phase 2.\nStudy: The Effectiveness of HP and TMZ 
 Synergism on Adult Recurrence GBM\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/haloperidol#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0621
 8524
URL:https://assetmemo.bio/drug/haloperidol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07726069-8908@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Haloperidol: Phase 1 readout est. (NCT07726069)
DESCRIPTION:Haloperidol\, phase 1.\nStudy: Haloperidol For Outpatient Sympt
 om Management in Patients Diagnosed With Cannabinoid Hyperemesis Syndrome 
 in the Emergrency Department\nEstimated primary completion: January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/haloperidol#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07726069
URL:https://assetmemo.bio/drug/haloperidol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07109245-8908@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Haloperidol: Phase 4 readout est. (NCT07109245)
DESCRIPTION:Haloperidol\, phase 4.\nStudy: Do Antipsychotics Block Insulin 
 Action in the Brain: is it a Class Effect?\nEstimated primary completion: 
 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/haloperi
 dol#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07109245
URL:https://assetmemo.bio/drug/haloperidol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03743649-8908@assetmemo.bio
DTSTAMP:20261121T004010Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Haloperidol: Phase 2/3 readout est. (NCT03743649)
DESCRIPTION:Haloperidol\, phase 2/3.\nStudy: Haloperidol and Lorazepam in C
 ontrolling Symptoms of Persistent Agitated Delirium in Patients With Advan
 ced Cancer Undergoing Palliative Care\nEstimated primary completion: 31 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/haloperi
 dol#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 03743649
URL:https://assetmemo.bio/drug/haloperidol#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
